RK
Therapeutic Areas
MeiraGTx Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AAV2-hAQP1 | Grade 2/3 Radiation-Induced Xerostomia (RIX) | Phase 3 |
| AAV-RPGR | X-Linked Retinitis Pigmentosa (XLRP) | Phase 3 |
| AAV-CNGB3 | Achromatopsia (CNGB3-related) | Phase 3 |
| AAV-CNGA3 | Achromatopsia (CNGA3-related) | Phase 3 |
| AAV-GAD | Parkinson's Disease | Phase 2 |
| Riboswitch Platform (e.g., GLP-1) | Obesity/Diabetes | Preclinical/Research |
| Riboswitch Platform (CAR-T) | Oncology / Autoimmune | Preclinical/Research |
Leadership Team at MeiraGTx
AF
Alexandria Forbes, Ph.D.
President and Chief Executive Officer
RG
Richard Giroux
Chief Operating Officer and Chief Financial Officer
SN
Stuart Naylor, Ph.D.
Chief Development Officer
RW
Robert Wollin, JD
General Counsel and Secretary
KR
Keith R. Harris, Ph.D.
Chairman of the Board
EH
Ellen Hukkelhoven, Ph.D.
Board Member